Its drug delivery technologies include synthetic polymer targeted delivery, vitamin mediated targeted delivery, vitamin mediated oral delivery, bioerodible cross-linker technology, mucoadhesive disc technology, hydrogel particle aggregate technology, and residerm topical delivery.
The company’s development stage product candidates include polymer palatinate that is used in the treatment of cancers; and DACH platinum, which is used in the treatment for metastatic colorectal cancer.
It also has amlexanox patents and technology for the treatment of mucosal and skin disorders.
In addition, Access Pharmaceuticals offers amlexanox 5% paste for the treatment of canker sores; and Zindaclin for the treatment of acne, as well as OraDisc, a drug delivery system to treat canker sores.
The company is based in Dallas, Texas.